The value of biological drugs indicated for autoimmune diseases, which affect up to 5% of the total world population, was roughly $11 billion in 2005. Remicade, Enbrel, Humira and Avonex currently lead the autoimmune field.
Inflammation/Autoimmune Disease Reports
Rheumatoid arthritis, a systemic disease characterized by inflammation of the membrane lining the joint, is one of the most common forms of arthritis. Up to 50 percent of all rheumatoid arthritis patients enter early retirement within five years of diagnosis, which means that the indirect costs associated with this disease can be very high.